4 awards, 70.9 million manats, one supplier — a 94.5% concentration signal at a national hematology centre
AZTender's data cut of 28 September 2026 shows Azerbaijan's National Hematology and Transfusiology Center sent 94.5% of 12-month awards — 70,891,345.05 of 75,023,480.55 AZN — to one supplier under three name variants.
AZTender's data cut of 28 September 2026 shows Azerbaijan's National Hematology and Transfusiology Center ("Milli Hematologiya və Transfuziologiya Mərkəzi" Publik Hüquqi Şəxsi), a public legal entity, directing 70,891,345.05 AZN of its 75,023,480.55 AZN in deduplicated 12-month award value — 94.5% — to a single supplier registered under three name variants of AVROMED COMPANY. The largest of the four awards, 36,861,414.18 AZN for medicines, reagents and medical consumables under the Blood Disorders and Thalassemia state programmes, was published on 18 September 2026, about ten days before this data cut, and the listing is now closed and archived.
The numbers
| Item | Value |
|---|---|
| Buyer | National Hematology and Transfusiology Center ("Milli Hematologiya və Transfuziologiya Mərkəzi" Publik Hüquqi Şəxsi) |
| Supplier, registered name variants | 3 ("AVROMED COMPANY" MMC, "AVROMED COMPANY" QSC, Avromed Company MMC) |
| Combined value, 4 distinct awards | 70,891,345.05 AZN |
| Buyer's 12-month total, all suppliers (33 distinct awards) | 75,023,480.55 AZN |
| Supplier's share of buyer's 12-month total | 94.5% |
| Largest single award, published 18 September 2026 | 36,861,414.18 AZN |
What the number is not
These are announced award values from result records, not confirmed signed-contract payments; the registry shows no matching contract date for the 18 September award, so execution is unconfirmed. The 94.5% figure describes one buyer's awards to one normalised supplier name, not a "Bir mənbə" (single-source) claim — the registry's procedure-type field carries no tag on the largest award. It is not a bidder-count or competition claim, since Azerbaijan's open procurement data carries no reliable bidder counts. The three name variants were grouped by normalised name — legal-form and case differences only — never by tax identification number.
Why it is a signal
- Are the three registered name variants the same legal entity, and why does the registry list them separately?
- What procedure governed each award, given the largest carries no procedure-type tag?
- Did the 18 September award, still without a contract date, convert into a signed, executed contract?
- Is a supplier taking 94.5% of one buyer's annual awards typical of this rare-disease drug programme, or specific to this year?
- How many suppliers in Azerbaijan can supply Blood Disorders and Thalassemia programme drugs and reagents at this scale?
What AZTender shows
AZTender's entity-report module links every result record naming a supplier's registry name — including case and legal-form variants the registry does not merge automatically — to the buyer history behind it, so four awards worth 94.5% of one buyer's annual total surface as a single buyer-scoped pattern rather than four separate portal entries. A bidder assessing the market for rare-disease drug and reagent supply, or an auditor screening health-sector buyers for concentration, can pull that entity report instead of rebuilding the record set by hand. More detail is available at aztender.ai.
A signal is not a verdict. A single specialised supplier repeatedly winning awards at a national reference centre for a rare-disease drug programme can have an ordinary explanation, such as a narrow supplier market for these specific drugs and reagents, and no conclusion about wrongdoing, affiliation or overpricing is drawn here.
